Shanghai Fudan Forward S&T Co

Shanghai Fudan Forward S&T Co FCF Yield

The Free Cash Flow Yield of Shanghai Fudan Forward S&T Co (600624.SS) as of Oct 29, 2026 is -1.51 %. In the previous year, Free Cash Flow Yield was -0.54 % — a change of 180.88% (lower).

FCF Yield

-1.51 %

YoY

180.88%

Last updated:

Free Cash Flow Yield of Shanghai Fudan Forward S&T Co is 2025 -1.51 % . Free Cash Flow Yield of Shanghai Fudan Forward S&T Co was 2024 -0.54 % . It decreases by 180.88% lower compared to the previous year.

The Shanghai Fudan Forward S&T Co FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
3.11 CNY
Jan 1, 2019
0.15 CNY
Jan 1, 2020
1.11 CNY
Jan 1, 2021
0.52 CNY
Jan 1, 2022
0.20 CNY
Jan 1, 2023
-0.01 CNY
Jan 1, 2024
-0.54 CNY
Jan 1, 2025
-1.51 CNY
The Shanghai Fudan Forward S&T Co FCF Yield history
YEARFCF YieldYoY
-1.51 %+180.88%
-0.54 %+3,938.30%
-0.01 %-106.55%
0.20 %-61.18%
0.52 %-52.69%
1.11 %+620.71%
0.15 %-95.05%
3.11 %+53.91%
2.02 %-197.95%
-2.06 %+290.83%
-0.53 %-79.97%
-2.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Fudan Forward S&T Co Stock analysis

What does Shanghai Fudan Forward S&T Co do? Shanghai Fudan Forward S&T Co., Ltd. generates revenue through the research, development, production, and sale of pharmaceutical products, including digestive system drugs, nervous system drugs, antineoplastic drugs, circulatory drugs, and immune function medications. The company also provides financial insurance software products. Its domestic and overseas markets serve as key sales channels for these pharmaceuticals and software solutions. The firm's product portfolio targets healthcare providers, hospitals, and pharmacies within the pharmaceutical sector. The company's pharmaceutical segment focuses on specialized drug categories such as digestive system and nervous system treatments, alongside antineoplastic and circulatory drugs. Financial insurance software products complement its core pharmaceutical business, offering additional revenue streams. Domestic markets account for a significant portion of sales, while overseas markets expand its global reach. Shanghai Fudan Forward S&T Co., Ltd. leverages its 1,426 full-time employees to support both pharmaceutical and software operations. The firm's product offerings cater to healthcare institutions requiring specialized medications and digital solutions for insurance management. This dual focus allows the company to serve multiple segments within the healthcare and financial technology industries. Shanghai Fudan Forward S&T Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai Fudan Forward S&T Co stock

Free Cash Flow Yield of Shanghai Fudan Forward S&T Co is -1.51 % in 2025.

Free Cash Flow Yield of Shanghai Fudan Forward S&T Co changed from -0.54 % to -1.51 %, representing a 180.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Shanghai Fudan Forward S&T Co since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Shanghai Fudan Forward S&T Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Shanghai Fudan Forward S&T Co

All Key Metrics — Shanghai Fudan Forward S&T Co